This recognition highlights the breakthrough of the company’s Microcrystalline Cellulose (MCC) production at their new production facility, powered by the patented AaltoCell™ technology.
ESPOO, Finland (October 9th, 2024) Nordic Bioproducts Group (NBG) has announced that it was selected as one of the finalists at the CPHI Pharma Awards 2024 in the sustainability category. The recognition came from the company’s pioneering work at their new production facility in Lappeenranta, Finland, where NBG’s Microcrystalline Cellulose (MCC) is being produced, amongst others, for the pharmaceutical, nutraceutical, cosmetics, food, and bioplastics industries.
“We are extremely proud to receive this recognition from one of the world’s leading pharmaceutical ecosystem players. We invested a lot of time and effort in perfecting our MCC production to exceed the highest standards. Now, we are ready to ship our product that meets with the utmost quality with top performance and sustainability,” says Olli Kähkönen, CEO and co-founder of Nordic Bioproducts Group.
Featuring the world’s first continuous production line of up to 10,000 tons of MCC annually, NBG’s Lappeenranta facility was designed to ensure quality and purity in MCC production. It prioritizes environmental sustainability by producing zero solid waste and using only a fraction of the chemicals, water, and electricity compared to traditional MCC production processes. Furthermore, based on the findings of an independent third-party study, the process achieves a significant 81% reduction in greenhouse gas emissions compared to traditional methods.
The PURA Series™ from NBG provides a diverse selection of MCC products tailored to the pharmaceutical industry and beyond. The premium PURA Series™ Super Flow products feature a spherical particle shape and high bulk density, which significantly enhance flowability.
The PURA Series tackles multiple vital things for the pharmaceutical and nutraceutical industries. It has high compressibility and density that enables the production of stronger, smaller tablets while optimizing batch sizes. Additionally, the PURA Series has improved disintegration which facilitates optimal release of active ingredients for better efficacy. It has excellent flowability, ensuring efficient production processes and minimizing downtime. Finally, the low dust formation promotes a cleaner manufacturing environment. This combination of features makes the PURA Series™ ideal for various applications, enhancing both safety and performance in production.
In 2024, the production of MCC has been making waves in the pharmaceutical industry. In June, NBG announced that it had received the prestigious EXCiPACT™ certification for the production of MCC. EXCiPACT™ is an independent, nonprofit association that provides management oversight for the third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide.
NBG received the certification following a comprehensive audit. It demonstrates that its site manufactures and distributes Microcrystalline Cellulose (MCC-AaltoCellTM) for the pharmaceutical industry according to the 2021 EXCiPACT Certification Standard for Pharmaceutical Excipient Suppliers.
NBG will be one of the exhibitioners at the CPHI Milan event in early October, at booth 6D10.
“We are ready to connect with companies looking for compounds and ingredients that can be traced all the way back to where they were sourced from. Our early experiments show that our MCC has qualities that are not found in the current tablet formulations, for example. This is a testament to our ongoing investment into research and development, without skipping the important test of being a responsible and sustainable option,” Kähkönen concludes.
###
For additional information:
Media kit with pictures
Minna Laitinen
CCO
Nordic Bioproducts Group
minna.laitinen@Nordic Bioproducts Group.fi
About Nordic Bioproducts Group
Nordic Bioproducts Group Oy (“Nordic Bioproducts Group”), founded in 2019 as a spin-off from Aalto University, stands at the forefront of cellulose innovation, bioproduct development, and commercialization in the Nordics.
At the heart of its mission is a commitment to optimizing the use of renewable natural resources while reducing the world’s dependence on fossil-based resources, fostering circular solutions, and catalyzing impactful change on a global scale.
As a pioneering force, the company is dedicated to introducing breakthrough technologies and biomaterials that redefine the landscape of sustainable solutions.
The company’s head office is in Espoo, Finland. More information: nordicbioproducts.fi
